Nutritional Supplement Study for Healthy Adults

This study is looking at how a special nutritional supplement affects nicotinamide adenine dinucleotide (NAD+) levels in healthy adults. NAD+ is a molecule important for energy and cell health. You would take either the "Proprietary Nutritional Supplement" (1000 mg of nicotinamide metabolites and plant extracts) or a "Placebo Supplement" (1000 mg of maltodextrin, an inactive substance) every day for 60 days. Researchers will measure your NAD+ levels in your blood to see if the supplement makes a difference. They are particularly interested in changes from the beginning of the study to day 14. This study is for healthy adults between 45 and 65 years old. The study is currently unclear on its recruitment status and plans to enroll 34 people.

Study design
This study is an interventional study, meaning participants will receive a specific treatment. It involves 34 participants who will be randomly assigned to receive either the active supplement or a placebo.
What's involved
You would take a supplement by mouth daily for 60 days. Your NAD+ levels in whole blood will be measured at the start of the study and again at day 14.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure your NAD+ levels up to day 14 after starting the supplement.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07428889

Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement

Completed
NAAges 45–65Interventional
Shaklee Corporation
~29 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:Proprietary Nutritional SupplementPlacebo Supplement

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Nicotinamide adenine dinucleotide response in whole blood
Measured over Baseline to Day 14
Healthy Adult

NCT07428889

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Biofortis Clinical Research

    Addison, Illinoisno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Erin Barrett, PhD · STUDY_DIRECTOR · Shaklee Corporation

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Nicotinamide adenine dinucleotide response in whole bloodBaseline to Day 14